Nitric oxide (NO) is a small, diffusible molecule with outsized importance in vascular biology and tissue repair. Produced by endothelial cells lining blood vessels, NO plays a critical role in vasodilation, endothelial cell migration, and the formation of new blood vessels (angiogenesis). Peptides like BPC-157 and TB-500 that modulate NO signaling have become subjects of intense research interest. This guide explains the NO signaling pathway and how it supports tissue recovery.
Nitric oxide (NO) is a free radical gas (one unpaired electron) synthesized by three nitric oxide synthase (NOS) enzymes:
In the context of tissue repair, we are primarily interested in eNOS-derived NO from endothelial cells, which supports healing.
Once synthesized, eNOS-derived NO diffuses across the endothelial cell membrane into adjacent smooth muscle cells lining the blood vessel wall. Inside the muscle cell, NO activates soluble guanylate cyclase (sGC), an enzyme that catalyzes the synthesis of cyclic guanosine monophosphate (cGMP):
NO + sGC → cGMP ↑
cGMP is the key second messenger. Elevated cGMP activates protein kinase G (PKG), which phosphorylates downstream targets including:
The net result: the blood vessel widens (vasodilation), increasing blood flow to the tissue. For a healing wound, more blood flow means more oxygen and nutrients delivered to reparative cells.
eNOS-derived NO is the dominant vasodilator signal in most tissues. By widening blood vessels, it increases perfusion to ischemic (oxygen-deprived) areas. In a healing wound, restoring blood flow is one of the first priorities — ischemia is a barrier to all other repair processes.
NO is a pro-angiogenic signal. It does this in part by:
Without adequate NO signaling, new blood vessels form poorly and repair is delayed.
In the early inflammatory phase of repair, immune cells must exit the bloodstream and infiltrate the wound. NO modulates endothelial permeability by altering tight junctions and adhesion molecules, facilitating this recruitment. However, excessive permeability (driven by inflammatory iNOS-NO) can cause edema and excessive inflammation, so balance is critical.
NO inhibits platelet activation and clotting. This is beneficial in moderation (prevents micro-thrombosis), but loss of NO can promote pathological thrombosis (clot formation in blood vessels).
Several research peptides interact with or enhance eNOS-derived NO production:
BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from gastric juice. Preclinical research shows that BPC-157 promotes eNOS activation and increases NO availability. One proposed mechanism involves activation of the Src-caveolin-1-eNOS signaling axis, a pathway in which the kinase Src phosphorylates caveolin-1, which in turn relieves inhibition of eNOS. The result is enhanced NO production and downstream vasodilation and angiogenesis. BPC-157 has shown promise in wound-healing models in multiple tissues (skin, tendon, muscle, gastrointestinal tract).
TB-500 is a 43-amino-acid thymus-derived peptide that regulates actin polymerization and endothelial cell motility. Some research suggests TB-500 enhances eNOS signaling indirectly through its effects on vascular remodeling and growth factor signaling. TB-500's wound-healing benefits may be partly NO-dependent, though its primary mechanism relates to actin-binding and cell migration.
The copper-peptide complex GHK-Cu is known to enhance collagen synthesis and wound healing. Some mechanistic work suggests that GHK-Cu may upregulate growth factors that stimulate eNOS; however, its direct effects on NO are less well-characterized than those of BPC-157.
It is important to note that NO is context-dependent:
An effective tissue-repair peptide likely enhances eNOS-dependent signaling while avoiding excessive iNOS activation. This nuance is why reading the mechanistic details of a study (which NOS isoform was measured? were inflammatory markers assessed?) is critical to interpreting results.
Shop tissue repair peptides →